XPhyto (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to share news the company has delivered 2,000 of its test kits to an Israeli distributor to work on clinical evaluation and seek regulatory approval.
Rogers telling Proactive the clinical evaluation process is expected to be complete in less than 90 days and will be the basis for commercial approval in Israel.